Prognostic Factors in EGFR-Mutant mNSCLC and Marathon Approach

In this segment, the panel emphasizes the long-term, “marathon” nature of EGFR-mutant mNSCLC therapy, highlighting the importance of first-line optimization. Experts discuss prognostic factors that may guide therapy intensity, including CNS and liver metastases, high tumor burden, and molecular markers such as p53 mutations. They stress that combination therapy benefits all patient populations, not only high-risk individuals. Panelists outline strategies for sequencing therapies over time, noting that subsequent lines of treatment are less effective, which underscores the need to maximize outcomes upfront. Shared decision-making, monitoring for adverse events, and adjusting therapy based on patient response are emphasized as central to long-term management. The discussion also highlights the need to break therapy into manageable segments, ensuring patients maintain adherence and tolerability throughout the course of treatment. Overall, this segment provides a framework for treating EGFR-mutant mNSCLC as a long-term endeavor, balancing efficacy, patient experience, and durable disease control to achieve optimal outcomes over the entire treatment continuum.